Introduction
============

Human milk (HM) is the gold standard of early infant nutrition. The World Health Organization ([@bib34]) and the American Academy of Pediatrics ([@bib18]; [@bib5]) recommend that infants be exclusively breastfed for the first 6 months of life. However, this recommendation is not consistently achieved; reported rates of exclusive breast feeding at 6 months of age range from 10 to 46% ([@bib34]; [@bib18]). The World Health Organization and AAP recognize infant formula as a suitable feeding alternative when HM is not available ([@bib34]; [@bib5]). Mixed feeding (breastfed and infant formula) does occur, and it is estimated that between 35 and 50% of the infants receive some feedings of infant formula during the first 6 months of life ([@bib3]; [@bib27]). Given the number of infants receiving mixed feedings (HM and formula), and the importance of early life nutrition for optimal growth and development, continued research related to the composition of infant formula and health outcomes of formula fed (FF) infants is warranted.

One of the areas in which HM and infant formula differ is in protein composition and concentration. Mature HM provides 10--12 gm/l total protein ([@bib20]; [@bib24]; [@bib6]; [@bib9]) and is rich in essential amino acids. Standard infant formulas are typically made from cow\'s milk, which has a higher total protein concentration and contains a different amino acid profile than HM. A higher total protein concentration in infant formula (14--15 gm/l) has been necessary to provide sufficient quantities of all the essential amino acids.

Higher protein concentration in infant formula is hypothesized to be a factor that contributes to growth differences observed between FF- and HM-fed infants ([@bib17]). FF infants tend to have higher post prandial ([@bib31]) and fasting ([@bib23]; [@bib13]; [@bib1]) concentrations of branched chain amino acids compared with HM-fed infants. Plasma concentrations of these amino acids have been positively correlated with insulin release ([@bib11]), and insulin is known to increase cellular glucose uptake and inhibit lypolysis. These metabolic alterations are proposed mechanisms for greater weight gain and greater weight-for-length *z*-scores (WLZ) or body mass index in FF infants compared with HM-fed infants ([@bib21]). Rapid weight gain, upward crossing of growth percentiles and a greater weight-for-length at 6 months have been identified as risk factors for overweight and obesity, later in life ([@bib29], [@bib28]; [@bib16]; [@bib30]).

The primary limiting factor in reducing the total protein concentration in infant formula is the ability to provide sufficient quantities of essential amino acids. This can, in part, be addressed by enriching whey protein fractions in formula with substantially higher concentrations of α-lactalbumin; α-lactalbumin is the predominant whey protein found in HM and is a rich source of essential amino acids ([@bib19]). α-Lactalbumin accounts for 28% of the total protein in HM and only 3% of the total protein in bovine milk ([@bib14]). Human and bovine α-lactalbumin share 72% amino acid sequence homology and both consist of 123 amino acids ([@bib10]). Infants fed a formula enriched with bovine α-lactalbumin (14 g/l protein, 2.2 g/l α-lactalbumin) demonstrated appropriate growth and biomarkers of protein status ([@bib19]), as well as good gastrointestinal tolerance to the formula ([@bib7]). It was notable that the plasma amino acid concentrations in the infants consuming the 14 g/l protein formula were similar to but slightly higher than those fed HM ([@bib7]). These data suggested that a further reduction in protein concentration of an α-lactalbumin-enriched formula might be achievable, while still supporting appropriate growth.

This study sought to evaluate the safety and efficacy of a new, lower protein, α-lactalbumin-enriched formula. The primary hypothesis was that weight gain of infants fed this lower protein experimental formula (EF) would be less than but within 3 g/day of those fed the higher protein standard formula (SF), which in addition to other parameters, would indicate that the lower protein concentration was indeed suitable for term infants. We also sought to evaluate whether the modest reduction in the formula\'s total protein concentration would result in growth outcomes in EF infants that were similar to HM-fed infants.

Subjects and methods
====================

Study design
------------

This study was a randomized, controlled, double-blind study of healthy term FF infants; FF infants were randomized to receive either SF or EF, and a HM group was included as a reference. The protocol and informed consent form were reviewed and approved by the National Ethics Committee and the Bureau of Food and Drugs in the Philippines. Written informed consent was obtained from the parent or legal guardian of each infant before enrollment.

Subjects
--------

Inclusion criteria required that infants were at birth, a singleton and term infant; at enrollment were 5--14 days of age, and had a weight, length and head circumference ⩾fifth and ⩽ninety-fifth percentile for age according to Filipino growth reference standards ([@bib35]), and exclusively consuming and tolerating a cow\'s milk infant formula (to be eligible for FF group), or exclusively consuming and tolerating HM (to be eligible for HM group). Main exclusion criteria included: a family history of allergy to a cow\'s milk protein formula, major congenital malformations, infection or other systemic disorders.

Methods
-------

### Randomization

Allocation of FF infants to one of the two study formulas proceeded through the use of a gender-stratified randomization schedule. To ensure double blinding, the packaging of the study formula was identical aside from the package number. Formula feeding began after randomization (baseline) and continued for 120 days.

### Nutrient composition of study formulas

Study formulas, standard S-26 GOLD (SF) or experimental S-26 GOLD (EF) (Wyeth Nutrition, Askeaton, Ireland) were packaged in 250 ml ready-to-feed Tetra Brik cartons (Tetra Pak, Lund, Sweden). The main difference between the formulas ([Table 1](#tbl1){ref-type="table"}) was the total protein concentration. The ability to provide the required amount of essential amino acids in a formula with a lower protein concentration was achieved primarily through enrichment of the formula with α-lactalbumin and supplementation with small amounts of -tyrosine and -tryptophan. The vitamin and mineral concentrations of the study formulas were similar. Both formulas satisfied the essential composition requirements of Codex and EU Commissions ([@bib4]; [@bib8]) and the US Infant Formula Act ([@bib33]).

### Anthropometric measures

Weight, recumbent length and head circumference were measured at baseline, days 30, 60, 90 and 120. Weight of naked infants was measured on an infant scale (Seca 374, Hamburg, Germany), recumbent length was measured on a pediatric length board (Ellard Instrumentation, Washington, DC, USA) and head circumference was measured utilizing a pediatric tape measure (Seca 212, Hamburg, Germany). All anthropometric measures were taken twice at each visit and the mean was calculated.

### Serum/plasma biochemistries

Blood samples were collected at baseline, study days 60 and 120. At day 60, a timed blood sample (2 h post-prandial) was collected to assess plasma essential and conditionally essential amino acids, insulin and glucose concentrations. Serum chemistries were analyzed by spectrophotometry, serum insulin was measured by radioimmunoassay and serum glucose was measured by spectrophotometry (Quest Diagnostics Clinical Trials, Valencia, CA, USA). Plasma amino acids were analyzed by ion-exchange chromatography with the exception of tryptophan, which was analyzed by tandem liquid chromatography mass spectroscopy (Mayo Clinical Trial Services, Rochester, MN, USA).

### Study events

Study events were recorded throughout the study. A study event was defined as any untoward, undesired or unplanned event in the form of signs, symptoms, disease or laboratory or physiological observations occurring in a person given a test article (study formula) or enrolled in the study. The investigator assigned each event as 'related\' if there was a reasonable causal relationship to the test article, or 'not related\' if there was not a reasonable causal relationship to the test article. A subset of symptoms related to the digestive system and gastrointestinal tolerance were identified of particular interest *a priori*: hard stool, constipation, difficulty having a bowel movement, acute diarrhea, chronic diarrhea, spitting up, regurgitation, vomiting, gastroesophageal reflux disease, colic and crying/neonatal abnormal crying. To ensure consistency in diagnosis, investigators were provided with standard definitions for these symptoms.

### Data management

Data management was performed by Accenture (Philadelphia, PA, USA). Remote data capture was used to electronically record data; study monitors verified data in RDC against the source data and identified and resolved discrepancies. Data collection, data entry, query process, data review and database lock were performed according to standard operating procedures.

### Statistical analysis

Data analysis was conducted as outlined in the statistical analysis plan utilizing SAS software version 9.1.3 (Cary, NC, USA). Analysis populations were defined as follows, intent to treat: subjects with a randomization number and efficacy analyzable: all randomized infants who took at least one feed of the study formula and have a measurable primary endpoint. Anthropometric measures were evaluated as raw data and also expressed as *z*-scores relative to the growth standards of the World Health Organization (WHO Multicentre Growth Reference 2006) using a World Health Organization software program (<http://www.who.int/childgrowth/software/en/>). Baseline *z*-score values are raw means; study day *z*-score values are adjusted means based on an ANCOVA with baseline and feeding group in the model.

Comparison between the EF and SF groups was of interest, as was the comparisons between each formula group and the HM group. Analyses were conducted as independent sets of pairwise comparisons because the HM group was included as a reference group and was not a randomized group. A sample size of 90 subjects per arm (45 subjects per gender per arm) was required to have 80% power to detect a difference in weight gain of 3 g/day (baseline to day 120) between groups, when testing at an α level of 0.025 (one-tailed). The error rate was held constant at the α=0.05 level for all outcomes. Given the multiple *t*-tests performed for the plasma essential amino acid analysis, results are also present using the Bonferroni adjustment for multiplicity *α*~adj~=0.0015.

Results
=======

Subject disposition, study events and subject demography
--------------------------------------------------------

Of the 336 infants enrolled (112 infants per group), 321 infants completed the study (96%). The number of discontinuations for study events was low and not significantly different between groups (2.7, 2.7 and 0% in the SF, EF and HM groups, respectively). The primary safety endpoint was the frequency of study events; study events were distributed across all treatment groups. A total of 25 treatment-related gastrointestinal (GI) study events occurred (see Methods): 6.3% in the EF group, 11.6% in the SF group and 4.5% in the HM group. Baseline infant characteristics were comparable between the groups ([Table 2](#tbl2){ref-type="table"}), with the exception of birth weight, which was significantly higher in the formula groups compared with HM (*P*=0.005, HM vs EF or SF). Mothers of FF infants gained significantly (*P*=0.014) more weight during pregnancy compared with mothers of HM-fed infants (EF: 11.8 kg, SF: 11.2 kg and HM: 10.2 kg).

Growth velocity
---------------

Mean weight gain (baseline to day 120 g/day) did not significantly differ between neither EF vs SF (*P*=0.67) nor EF vs HM (*P*=0.11); however, weight gain was significantly greater in the SF vs HM group (*P*=0.04) ([Table 3](#tbl3){ref-type="table"}). Mean length gain (baseline to day 120) was comparable and did not significantly differ between EF vs SF. Mean length gain of the EF group was slightly greater than that of the HM infants (*P*=0.03).

*Z*-scores
----------

At baseline, there were no significant differences between the EF and SF groups in weight-for-age *z*-score (WAZ), length-for-age *z*-score, head circumference-for-age *z*-score or WLZ ([Figure 1](#fig1){ref-type="fig"}). Both formula groups were significantly higher than HM group at baseline for WAZ (*P*=0.008 and *P*=0.012 for EF and SF, respectively) and head circumference-for-age *z*-score (*P*=0.03 and *P*=0.003 for EF and SF, respectively). The mean WLZ of SF group was significantly higher than the HM group (*P*=0.03) at baseline.

At day 120, there were no significant differences between the EF and SF groups for any mean *z*-score parameters (adjusted for baseline). The adjusted mean WAZ of the SF group was significantly higher than the HM group (mean difference 0.245, *P*=0.03). The adjusted mean length-for-age *z*-score of the EF and SF groups were significantly higher than the HM group (mean difference 0.269 and 0.243, *P*=0.001 and *P*=0.002, for EF and SF groups, respectively). The adjusted mean head circumference-for-age *z*-score of the EF and SF groups were significantly higher than HM (mean difference 0.227 and 0.219, *P*=0.007 and *P*=0.009 for EF and SF groups, respectively). There was no significant difference in the adjusted mean WLZ for either formula group against HM at study day 120.

Serum biochemistries and amino acids
------------------------------------

Mean concentrations of serum albumin, total protein, blood urea nitrogen and creatinine were within the normal range for all groups at all time points ([Table 4](#tbl4){ref-type="table"}). Mean concentrations of glucose and insulin did not differ between groups. There were no significant differences in the mean amino acid concentrations between the EF and SF groups ([Table 5](#tbl5){ref-type="table"}). EF and SF infants had a significantly greater concentrations of some amino acids (lysine, methionine, phenylalanine and threonine) compared with the HM group, however, the mean concentrations of these amino acids were within the normal range for all groups. In general, the plasma essential amino acid concentrations of both the EF and SF formula groups were similar to and within one s.d. of the HM group.

Discussion
==========

This study demonstrated that healthy term infants fed a new lower protein formula (EF) had an age-appropriate growth, biomarkers of protein status and biochemistries were normal, and no difference in the incidence of study events compared with the SF and HM groups. Weight gain with the new lower protein formula (EF) was intermediate between SF and HM groups; infants who consumed the new formula had weight gain, WAZ and WLZ similar to the HM-fed infant. This study compared growth of infants fed formulas that had a very modest difference (∼10%) in protein concentration; both formulas were found to be safe and support growth, but notably the weight gain in the lower protein (EF) group was not significantly different from the HM group.

Evidence of a positive relationship between the protein concentration of feeding and weight gain is hypothesized ([@bib17]), and supported by the results of randomized and observational studies. In prospective randomized trials, infants receiving a higher protein formula have been shown to have greater weight gain ([@bib24]; [@bib2]) or greater WAZ ([@bib17]) compared with infants receiving a lower protein formula. Randomized trials that have not found this difference ([@bib15]; [@bib23]; [@bib32]) tended to have a smaller difference in protein concentration between the formulas as well as a smaller sample size. In observational cohort studies, a higher protein intake ([@bib12]) and a higher percentage of dietary energy as protein ([@bib25]; [@bib26]) have been associated with overweight or increased body mass index at an age of 5--8 years, and an association between weight gain in infancy and later life obesity has also been shown ([@bib29]; [@bib22]). In summary, the literature suggests that the protein concentration of infant feeding has a role in weight gain during infancy, which in turn may have effect on weight in later life; this underscores the importance of the results of weight gain observed in the lower protein (EF) group in this study.

The difference in weight gain between the EF and SF groups was 0.3 g/day and although this represents only a modest reduction on a daily basis, it is cumulative and may be meaningful when projected over a longer time period. Indeed, at the conclusion of the study the mean adjusted WAZ of infants fed EF was not significantly different from that of HM group, whereas those receiving the SF had significantly greater WAZ compared with that of HM group. Both the formula groups had a significantly greater rate of length gain and length-for-age *Z*-scores compared with that of the HM group. Although the formula groups were longer than their HM-fed counterparts, their weight was proportional to their length as demonstrated by no significant difference in the WLZ of either of the formula group against the HM group at the conclusion of the study.

The plasma essential and conditional amino acid concentrations of infants fed with EF were for the most part intermediate between the SF and HM groups. Higher concentrations of the branched chain amino acids leucine, isoleucine and valine have been positively correlated with insulin concentrations ([@bib11]), which in turn may affect weight gain. This study found no significant difference in insulin concentrations between any of the groups. Higher insulin concentration in FF infants compared with HM-fed infants found in an earlier study ([@bib21]) may be because of substantially higher total protein concentration of infant formulas at that time.

The strengths of this study include the sample size, gender stratification and completion rate. The completion rate exceeded the minimum sample size needed to test the primary hypothesis, and gender balance was achieved within each group. A limitation of the study relates to the duration of the clinical trial infants received the study formula until they were 4.5 months of age. We do not know whether the weight gain observed in the EF group will have an impact on weight status in later age.

In summary, a randomized clinical trial demonstrated that the new lower protein α-lactalbumin-enriched formula (EF) is appropriate for term infants as evidenced by age-appropriate growth, markers of protein status, plasma essential amino acid concentrations and gastrointestinal tolerance. Infants randomized to the lower protein formula had growth outcomes similar to HM-fed infants in terms of weight gain, WAZ and WLZ. These data suggest that a modest reduction in the total protein concentration of the formula has an effect on growth in the short term; further studies are needed to determine if the trend in weight gain observed in the EF group has an impact on weight status in later life.
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![*Z*-scores are based on the World Health Organization reference data ([@bib34]). (**a**) weight-for-age *Z*-score, (**b**) length-for-age *Z*-score, (**c**) head circumference-for age-*Z*-score, (**d**) weight-for-length *Z*-score. Baseline values are means; *P*-values are based on a two-sample *t*-test. Study day values are least square (LS) means (study day mean adjusted for baseline); *P*-value is based on ANCOVA with baseline value and feeding group in the model. Significance declared at *P*\<0.05; ^\*\*^Significant difference between SF and HM groups; ^\*^Significant difference between EF and HM groups.](ejcn2010236f1){#fig1}

###### Macronutrient composition of study formulas[a](#t1-fn2){ref-type="fn"}

                                                          *SF*    *EF*    *Recommendations*[b](#t1-fn3){ref-type="fn"}                             
  ------------------------------------------------------ ------- ------- ---------------------------------------------- -------------------- ----- ------
  Energy, kcal/l                                           672     666                        600                               700           600   700
  Protein: energy ratio, g protein per 100 kcal            2.1     1.9                        1.8                               3.0           1.8   3.0
                                                                                                                                                      
  *Protein, g/l*                                          14.1    12.8                     See above                         See above             
   Histidine, mg/100 kcal                                  51      45                          40                                             41      
   Isoleucine                                              113     103                         90                                             92      
   Leucine                                                 205     186                        166                                             169     
   Lysine                                                  182     170                        113                                             114     
   Threonine                                               122     110                         77                                             77      
   Tryptophan                                              36      37                          32                                             33      
   Methionine + cysteine[c](#t1-fn4){ref-type="fn"}        84      76                          61                                             62      
   Tyrosine + phenylalanine[d](#t1-fn5){ref-type="fn"}     176     170                        159                                             156     
  α-Lactalbumin, g/l                                       2.2     2.3                 No recommendations                No recommendations        
  Whey:casein                                             60:40   66:34                No recommendations                No recommendations        
  Carbohydrate, g/100 kcal                                10.8    10.8                        9.0                               14.0          9.0   14.0
  Fat, g/100 kcal                                          5.4     5.4                        4.4                               6.0           4.4   6.0

Abbreviations: EF, experimental formula; EU, European union; Min, minimum; Max, maximum; SF, standard formula.

Nutrient composition analyzed by Covance Laboratories, Madison, WI, USA; total protein calculated as total nitrogen × 6.25.

Codex and EU recommendations for infant formula composition are based on a compilation of published literature values on human milk composition.

The concentration of methionine and cystine/cysteine may be added together if the ratio between methionine and cystine is not greater than 2.

The concentration of tyrosine and phenylalanine may be added together if the ratio between tyrosine:phenylalanine is not greater than 2.

###### Subject demography by feeding group[a](#t2-fn2){ref-type="fn"}

                             *SF (*n=*112)*                           *EF (*n=*112)*                           *HM (*n=*112)*
  -------------------------- ---------------------------------------- ---------------------------------------- ----------------
  Gestational age (weeks)    38.5 (0.9)                               38.6 (0.8)                               38.6 (0.9)
  Birth weight (kg)          3.14 (0.42)[b](#t2-fn3){ref-type="fn"}   3.17 (0.43)[c](#t2-fn4){ref-type="fn"}   3.00 (0.40)
  Birth length (cm)          49.4 (2.0)                               49.5 (2.0)                               49.4 (1.7)
  Age at enrollment (days)   9.5 (3.0)                                9.5 (2.7)                                9.8 (3.0)
  Gender (% male)            50                                       50                                       50
  Race (% Asian)             100                                      100                                      100

Abbreviations: HM, human milk; EF, experimental formula; SF, standard formula; values presented are means (s.d.).

Intent-to-treat (ITT)population.

Significant difference between SF vs HM, *P*\<0.05 (*P*-value based on two-sample *t*-test).

Significant difference between EF vs HM, *P*\<0.05 (*P*-value based on two-sample *t*-test).

Differences observed for both ITT population (data shown in table) and efficacy analyzable population (data not shown).

###### Growth velocity by feeding group[a](#t3-fn2){ref-type="fn"}

                                 *SF (*n=*108)*                          *EF (*n=*103)*                           *HM (*n=*110)*
  ------------------------------ --------------------------------------- ---------------------------------------- ----------------
  Weight gain, g/day             28.1 (5.4)[b](#t3-fn3){ref-type="fn"}   27.8 (5.3)                               26.6 (5.4)
  Length gain, cm/month          3.21 (0.33)                             3.22 (0.35)[c](#t3-fn4){ref-type="fn"}   3.12 (0.32)
  Head circumference, cm/month   1.60 (0.20)                             1.61 (0.22)[c](#t3-fn4){ref-type="fn"}   1.55 (0.18)

Abbreviations: HM, human milk; EF, experimental formula; SF, standard formula; values presented are means (s.d.).

Efficacy analyzable population; growth velocity = rate of change from baseline to day 120.

Significant difference between SF vs HM group, *P*\<0.05 (*P*-value based on two-sample *t*-test).

Significant difference between EF vs HM group, *P*\<0.05 (*P*-value based on two-sample *t*-test).

###### Serum biochemistries by feeding group[a](#t4-fn2){ref-type="fn"}

                       *Units*     *SF (*n=*108)*                         *EF (*n=*103)*                          *HM (*n=*110)*
  ----------------- -------------- -------------------------------------- --------------------------------------- -----------------------------------------------
  *Albumin*                                                                                                       
   Baseline              g/l       40.0 (3.0)                             40.9 (2.5)                              40.5 (2.8)
   Day 60                          42.7 (2.2)                             42.6 (2.2)                              42.3 (2.3)
   Day 120                         44.5 (2.2)                             45.0 (2.3)[b](#t4-fn3){ref-type="fn"}   44.0 (2.1)
                                                                                                                   
  *Total protein*                                                                                                 
   Baseline              g/l       61.4 (4.6)                             61.9 (4.4)                              61.3 (4.5)
   Day 60                          61.4 (4.3)                             60.8 (6.3)                              61.2 (3.6)
   Day 120                         63.8 (4.0)                             64.1 (4.2)                              63.9 (4.2)
                                                                                                                   
  *BUN*                                                                                                           
   Baseline          mg per 100ml  8.4 (2.9)                              8.4 (2.3)                               8.8 (2.8)
   Day 60                          6.7 (1.3)[c](#t4-fn4){ref-type="fn"}   5.7 (1.4)                               5.3 (1.8)[c](#t4-fn4){ref-type="fn"}
   Day 120                         6.9 (1.8)[c](#t4-fn4){ref-type="fn"}   6.4 (1.8)[b](#t4-fn3){ref-type="fn"}    4.8 (1.4)[b,c](#t4-fn3 t4-fn4){ref-type="fn"}
                                                                                                                   
  *Creatinine*                                                                                                    
   Baseline             μmol/l     42.5 (9.5)                             41.7 (9.3)                              41.1 (8.1)
   Day 60                          26.8 (3.3)                             26.5 (3.5)                              27.1 (2.2)
   Day 120                         27.3 (3.2)                             26.9 (3.6)                              27.3 (2.3)
                                                                                                                   
  *Insulin*                                                                                                       
   Day 60               μU/ml      6.48 (4.18)                            7.35 (4.83)                             6.58 (4.47)
                                                                                                                   
  *Glucose*                                                                                                       
   Day 60            mg per 100ml  67.9 (10.1)                            68.1 (10.2)                             70.2 (8.84)

Abbreviations: BUN, blood urea nitrogen; HM, human milk; EF, experimental formula; SF, standard formula; values presented are means (s.d.).

Efficacy analyzable population.

Significant difference between EF vs HM, *P*\<0.05 (*P*-value based on two-sample *t*-test).

Significant difference between SF vs HM, *P*\<0.05 (*P*-value based on two-sample *t*-test).

###### Mean plasma essential amino acid concentrations by feeding group[a](#t5-fn2){ref-type="fn"}

                    *SF (*n=*108)*                                                          *EF (*n=*103)*                                       *HM (*n=*110)*
  ----------------- ----------------------------------------------------------------------- ---------------------------------------------------- ----------------
  Cystine, μmol/l   13.67 (7.24)                                                            13.80 (6.27)                                         12.47 (5.73)
  Histidine         85.36 (12.02)[b](#t5-fn3){ref-type="fn"}                                84.45 (12.89)                                        81.86 (9.61)
  Isoleucine        60.80 (2.64)[b,c](#t5-fn3){ref-type="fn"}[c](#t5-fn4){ref-type="fn"}    58.66 (13.86)[d](#t5-fn5){ref-type="fn"}             53.45 (12.52)
  Leucine           105.24 (19.37)                                                          101.59 (21.77)                                       104.23 (20.72)
  Lysine            193.74 (33.74)[b,](#t5-fn3){ref-type="fn"}[c](#t5-fn4){ref-type="fn"}   192.52 (39.71)[d,e](#t5-fn5 t5-fn6){ref-type="fn"}   169.93 (35.08)
  Methionine        33.73 (7.77)[b,](#t5-fn3){ref-type="fn"}[c](#t5-fn4){ref-type="fn"}     33.49 (6.76)[d,e](#t5-fn5 t5-fn6){ref-type="fn"}     29.99 (5.86)
  Phenylalanine     54.47 (8.06)[b,](#t5-fn3){ref-type="fn"}[c](#t5-fn4){ref-type="fn"}     52.83 (8.99)[d,e](#t5-fn5 t5-fn6){ref-type="fn"}     48.57 (9.65)
  Threonine         182.11 (44.02)[b,](#t5-fn3){ref-type="fn"}[c](#t5-fn4){ref-type="fn"}   183.65 (40.84)[d,e](#t5-fn5 t5-fn6){ref-type="fn"}   132.50 (29.42)
  Tryptophan        62.79 (13.13)                                                           64.78 (11.78)[d](#t5-fn5){ref-type="fn"}             60.89 (11.73)
  Tyrosine          79.86 (15.87)                                                           88.31 (21.48)[d,e](#t5-fn5 t5-fn6){ref-type="fn"}    77.95 (15.11)
  Valine            166.17 (27.44)[b,](#t5-fn3){ref-type="fn"}[c](#t5-fn4){ref-type="fn"}   154.26 (29.52)[d](#t5-fn5){ref-type="fn"}            143.75 (31.93)

Abbreviations: HM, human milk; EF, experimental formula; SF, standard formula; values presented are means (s.d.).

Efficacy analyzable population.

Significant difference between SF vs HM, *P*\<0.05 (*P*-value based on two-sample *t*-test).

Significant difference between SF vs HM adjusted for multiplicity, *P*\<0.0015 (*P*-value based on two-sample *t*-test).

Significant difference between EF vs HM, *P*\<0.05 (*P*-value based on two-sample *t*-test).

Significant difference between EF vs HM adjusted for multiplicity, *P*\<0.0015 (*P*-value based on two-sample *t*-test).
